# Jan A. Burger

Source: https://onco.cc/people/jan-burger/  
OnCo record `jan-burger` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients.

## Summary

Jan Burger is a haematologist and laboratory investigator at MD Anderson Cancer Center. He was first author of the 2015 New England Journal of Medicine report of RESONATE-2, which showed that ibrutinib improved progression-free and overall survival compared with chlorambucil in previously untreated older patients with CLL, establishing BTK inhibition as first-line therapy. His laboratory studies how the tissue microenvironment supports CLL cells.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: leukaemia; targeted-therapy; trialist
- Role: Haematologist, MD Anderson Cancer Center
- Specialisms: Chronic lymphocytic leukaemia; BTK inhibitors; Leukaemia microenvironment

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic lymphocytic leukaemia, first treatment](https://onco.cc/cancers/cll-treatment-naive/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [RESONATE-2](https://onco.cc/trials/resonate-2/)

---
JSON: https://onco.cc/api/v1/entities/jan-burger.json